New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2013
09:04 EDTALXAAlexza Pharmaceuticals receives marketing authorization for Adasuve in EU
Alexza Pharmaceuticals announced that the European Commission has granted marketing authorization for Adasuve. In the European Union, Adasuve, 4.5 mg and 9.1 mg inhalation powder loxapine, pre-dispensed, is authorized for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. The Adasuve marketing authorization requires that patients receive regular treatment immediately after control of acute agitation symptoms, and that Adasuve is administered only in a hospital setting under the supervision of a healthcare professional. Short-acting beta-agonist bronchodilator treatment should be available for treatment of possible severe respiratory side-effects.
News For ALXA From The Last 14 Days
Check below for free stories on ALXA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
09:09 EDTALXAAlexza Pharmaceuticals updates Adasuve inhalation powder marketing in Europe
Subscribe for More Information
September 8, 2014
07:26 EDTALXAMorgan Stanley to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use